CD19 and acute lymphoblastic leukemia: Moreover, preexisting CD19 isoforms in malignant progenitor cells can potentially contribute to antigen-negative relapse after CD19-targeted therapy, especially in BCR-ABL1-positive ALL patients [124, 125].